肿瘤电场治疗脑胶质瘤的临床研究进展

胶质母细胞瘤（GBM）是颅内最常见的原发性恶性脑肿瘤，具有高复发率和高死亡率。目前GBM的标准治疗方案为外科手术，然后放疗同步替莫唑胺（TMZ）化疗和进一步TMZ化疗。肿瘤电场治疗（TTFields）是一种新兴的肿瘤治疗方法，当与标准治疗方案联合时，GBM患者的无进展生存期和总生存期可以得到显著改善。基于多项临床研究结果，TTFields已经在国内外获批上市，且得到了相关指南和共识的推荐。本文将重点述评TTFields的发展及其在GBM治疗中的一系列临床研究，并展望其未来的研究方向。

Glioblastoma(GBM) is one of the most common primary intracranial malignant tumors with high recurrence rate and high mortality. The current standard treatment option is surgery, concurrent chemoradiotherapy, and adjuvant temozolomide chemotherapy. Tumor treating fields(TTFields ) is an emerging tumor treatment, and when combined with standard treatment, the progression-free survival and overall survival of GBM patients can be significantly improved. Based on the results of multiple clinical researches, TTFields has been approved for marketing in China and abroad, and has been recommended by guidelines and consensus. This article will focus on the development of TTFields and summarise the landscape of TTFields clinical trials in GBM.